- Home
- RMCF vs XCUR Comparison
RMCF vs XCUR Comparison
Compare RMCF & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | XCUR |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 13.7M |
| IPO Year | 2024 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RMCF | XCUR |
|---|---|---|
| Price | $1.13 | $1.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 168.4K | 42.3K |
| Earning Date | 06-16-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.88 | ★ 83.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.84 | $1.68 |
| 52 Week High | $2.99 | $9.50 |
Technical Indicators
Market Signals| Indicator | RMCF | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 37.15 | 33.71 |
| Support Level | $0.84 | $1.71 |
| Resistance Level | $1.79 | $3.40 |
| Average True Range (ATR) | 0.18 | 0.32 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 35.29 | 7.89 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About XCUR Exicure Inc.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.